3-(3,4-Dihydroxyphenyl)-2-methyl-L-alanineSesquihydrate , 2mMinDMSO , 555-30-6
Synonym(s):
3-(3,4-Dihydroxyphenyl)-2-methyl-L -alanine;Methyl-L -DOPA;Methyl-DOPA sesquihydrate;MK-351
CAS NO.：555-30-6
Empirical Formula: C10H13NO4
Molecular Weight: 211.22
MDL number: MFCD00004186
EINECS: 209-089-2
| Pack Size | Price | Stock | Quantity |
| 1ml | RMB159.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | ≥300 °C |
| Boiling point: | 350.89°C (rough estimate) |
| Density | 1.2545 (rough estimate) |
| refractive index | -14 ° (C=1, H2O) |
| storage temp. | Sealed in dry,2-8°C |
| solubility | Soluble to 75 mM in DMSO |
| pka | 2.28±0.26(Predicted) |
| form | powder to crystal |
| color | White to Almost white |
| Water Solubility | 10g/L(temperature not stated) |
| Merck | 14,6055 |
| BCS Class | 3 |
| CAS DataBase Reference | 555-30-6(CAS DataBase Reference) |
| EPA Substance Registry System | Methyldopa (555-30-6) |
Description and Uses
Methyldopa is an α-methoxylated derivative of levodopa that exhibits hypotensive action by reducing overall peripheral vascular resistance and reducing heart work. Antihypertensive action of methyldopa consists of the biotransformation of methyldopa into methylnoradrenaline (methylnorepinephrine), which acts as a “pseudo neurotransmitter.” The current, universally accepted point of view is that the action of methyldopa is carried out through the CNS, where methylnorepinephrine, a powerful stimulant of α-adrenergic receptors of the medulla, inhibits the vasomotor center.
It is prescribed for arterial hypertension and hypertensive crises.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
| WGK Germany | 3 |
| RTECS | YP2860000 |
| F | 10-23 |
| HS Code | 29181990 |
| Hazardous Substances Data | 555-30-6(Hazardous Substances Data) |
| Toxicity | LD50 oral in rabbit: 713mg/kg |
